

The Korean Society of Medical Oncology with ASCO Breakthrough Session

8th International Conference of the Federation of Asian Clinical Oncology

September 3 - 4, 2020 Seoul, Korea

• Name: Yongjun Cha

• Current Position & Affiliation: Staff Physician, Center for Colorectal

Cancer, National Cancer Center

• Country: Korea

• Educational Background:

1997-2003 M.D. Seoul National University College of Medicine 2007-2009 M.Sc., Seoul National University College of Medicine 2012- Current Ph.D. Candidate, Seoul National University College of Medicine

• Professional Experience:

2004-2009 Intern/Resident, Internal Medicine, Seoul National University Hospital 2012-2013 Clinical Fellow, Hematology/Oncology, Seoul National University Hospital 2016- Current Staff Physician, Center for Colorectal Cancer, National Cancer Center

• Professional Organizations:

Korean Cancer Association, Korean Society of Medical Oncology, Korean Cancer Study Group, American Association for Cancer Research, American Society of Clinical Oncology, European Society of Medical Oncology

• Main Scientific Publications:

Kim, S.H. *et al.* Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. *Scientific Reports* 11, (2020).

Cha, Y. et al. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer. *Neoplasia (United States)* 21, (2019).

Cha, Y. et al. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro. Molecular Oncology 12, (2018).

Cha, Y. et al. Post-bevacizumab clinical outcomes and the impact of early discontinuation of bevacizumab in patients with recurrent malignant glioma. Cancer Research and Treatment 49, (2017).

Cha, Y. et al. Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. *British Journal of Cancer* 115, (2016).